Literature DB >> 9554879

Human P2Y1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites.

S Moro1, D Guo, E Camaioni, J L Boyer, T K Harden, K A Jacobson.   

Abstract

The molecular basis for recognition by human P2Y1 receptors of the novel, competitive antagonist 2'-deoxy-N6-methyladenosine 3', 5'-bisphosphate (MRS 2179) was probed using site-directed mutagenesis and molecular modeling. The potency of this antagonist was measured in mutant receptors in which key residues in the transmembrane helical domains (TMs) 3, 5, 6, and 7 were replaced by Ala or other amino acids. The capacity of MRS 2179 to block stimulation of phospholipase C promoted by 2-methylthioadenosine 5'-diphosphate (2-MeSADP) was lost in P2Y1 receptors having F226A, K280A, or Q307A mutations, indicating that these residues are critical for the binding of the antagonist molecule. Mutation of the residues His132, Thr222, and Tyr136 had an intermediate effect on the capacity of MRS 2179 to block the P2Y1 receptor. These positions therefore appear to have a modulatory role in recognition of this antagonist. F131A, H277A, T221A, R310K, or S317A mutant receptors exhibited an apparent affinity for MRS 2179 that was similar to that observed with the wild-type receptor. Thus, Phe131, Thr221, His277, and Ser317 are not essential for antagonist recognition. A computer-generated model of the human P2Y1 receptor was built and analyzed to help interpret these results. The model was derived through primary sequence comparison, secondary structure prediction, and three-dimensional homology building, using rhodopsin as a template, and was consistent with data obtained from mutagenesis studies. We have introduced a "cross-docking" procedure to obtain energetically refined 3D structures of the ligand-receptor complexes. Cross-docking simulates the reorganization of the native receptor structure induced by a ligand. A putative nucleotide binding site was localized and used to predict which residues are likely to be in proximity to agonists and antagonists. According to our model TM6 and TM7 are close to the adenine ring, TM3 and TM6 are close to the ribose moiety, and TM3, TM6, and TM7 are near the triphosphate chain.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9554879      PMCID: PMC3469197          DOI: 10.1021/jm970684u

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  22 in total

1.  Use of eukaryotic expression technology in the functional analysis of cloned genes.

Authors:  B R Cullen
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

2.  An all atom force field for simulations of proteins and nucleic acids.

Authors:  Scott J Weiner; Peter A Kollman; Dzung T Nguyen; David A Case
Journal:  J Comput Chem       Date:  1986-04       Impact factor: 3.376

3.  A simple method for displaying the hydropathic character of a protein.

Authors:  J Kyte; R F Doolittle
Journal:  J Mol Biol       Date:  1982-05-05       Impact factor: 5.469

4.  Helix to helix packing in proteins.

Authors:  C Chothia; M Levitt; D Richardson
Journal:  J Mol Biol       Date:  1981-01-05       Impact factor: 5.469

5.  Phosphoinositide hydrolysis by guanosine 5'-[gamma-thio]triphosphate-activated phospholipase C of turkey erythrocyte membranes.

Authors:  T K Harden; P T Hawkins; L Stephens; J L Boyer; C P Downes
Journal:  Biochem J       Date:  1988-06-01       Impact factor: 3.857

6.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

7.  A cDNA cloning vector that permits expression of cDNA inserts in mammalian cells.

Authors:  H Okayama; P Berg
Journal:  Mol Cell Biol       Date:  1983-02       Impact factor: 4.272

8.  Changes in the levels of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinositides.

Authors:  M J Berridge; R M Dawson; C P Downes; J P Heslop; R F Irvine
Journal:  Biochem J       Date:  1983-05-15       Impact factor: 3.857

9.  Site-directed mutagenesis identifies residues involved in ligand recognition in the human A2a adenosine receptor.

Authors:  J Kim; J Wess; A M van Rhee; T Schöneberg; K A Jacobson
Journal:  J Biol Chem       Date:  1995-06-09       Impact factor: 5.157

10.  Sequence and structure of yeast phosphoglycerate kinase.

Authors:  H C Watson; N P Walker; P J Shaw; T N Bryant; P L Wendell; L A Fothergill; R E Perkins; S C Conroy; M J Dobson; M F Tuite
Journal:  EMBO J       Date:  1982       Impact factor: 11.598

View more
  54 in total

Review 1.  Molecular recognition in P2 receptors: ligand development aided by molecular modeling and mutagenesis.

Authors:  K A Jacobson; C Hoffmann; Y C Kim; E Camaioni; E Nandanan; S Y Jang; D P Guo; X D Ji; I von Kügelgen; S Moro; A U Ziganshin; A Rychkov; B F King; S G Brown; S S Wildman; G Burnstock; J L Boyer; A Mohanram; T K Harden
Journal:  Prog Brain Res       Date:  1999       Impact factor: 2.453

Review 2.  Molecular recognition at purine and pyrimidine nucleotide (P2) receptors.

Authors:  Kenneth A Jacobson; Stefano Costanzi; Michihiro Ohno; Bhalchandra V Joshi; Pedro Besada; Bin Xu; Susanna Tchilibon
Journal:  Curr Top Med Chem       Date:  2004       Impact factor: 3.295

Review 3.  G protein-coupled adenosine (P1) and P2Y receptors: ligand design and receptor interactions.

Authors:  Kenneth A Jacobson; Ramachandran Balasubramanian; Francesca Deflorian; Zhan-Guo Gao
Journal:  Purinergic Signal       Date:  2012-02-29       Impact factor: 3.765

4.  The novel suramin analogue NF864 selectively blocks P2X1 receptors in human platelets with potency in the low nanomolar range.

Authors:  Susanne Horner; Kirsten Menke; Caren Hildebrandt; Matthias U Kassack; Peter Nickel; Heiko Ullmann; Martyn P Mahaut-Smith; Günter Lambrecht
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-09-13       Impact factor: 3.000

5.  Purine receptors: GPCR structure and agonist design.

Authors:  Kenneth A Jacobson; Soo-Kyung Kim; Stefano Costanzi; Zhan-Guo Gao
Journal:  Mol Interv       Date:  2004-12

6.  [32P]2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate ([32P]MRS2500), a novel radioligand for quantification of native P2Y1 receptors.

Authors:  Dayle Houston; Michihiro Ohno; Robert A Nicholas; Kenneth A Jacobson; T Kendall Harden
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

Review 7.  International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy.

Authors:  Maria P Abbracchio; Geoffrey Burnstock; Jean-Marie Boeynaems; Eric A Barnard; José L Boyer; Charles Kennedy; Gillian E Knight; Marta Fumagalli; Christian Gachet; Kenneth A Jacobson; Gary A Weisman
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

8.  Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells.

Authors:  E A Mellor; A Maekawa; K F Austen; J A Boyce
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

9.  Role of P2 purinergic receptors in synaptic transmission under normoxic and ischaemic conditions in the CA1 region of rat hippocampal slices.

Authors:  Elisabetta Coppi; Anna Maria Pugliese; Holger Stephan; Christa E Müller; Felicita Pedata
Journal:  Purinergic Signal       Date:  2007-01-03       Impact factor: 3.765

10.  Architecture of P2Y nucleotide receptors: structural comparison based on sequence analysis, mutagenesis, and homology modeling.

Authors:  Stefano Costanzi; Liaman Mamedova; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2004-10-21       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.